DOCSLIB.ORG

Morphine Indiscriminatingly Overstimulates All Opioid Receptors Including Those Not Involved in (Morphine) Pain Control (Exogenous)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Morphine Indiscriminatingly Overstimulates All Opioid Receptors Including Those Not Involved in (Morphine) Pain Control (Exogenous) Extensions des propriétés des inhibiteurs mixtes des enképhalinases aux douleurs de la sphère cranio-faciale. Nouvelles applications à la migraine et aux douleurs de la cornée. Bernard P. Roques Professeur Emérite, Université Paris Descartes Unité 1267 Inserm, 4 avenue de l’Observatoire, 75006 Paris. ATHS Biarritz, 1-4 Octobre 2019 CONFIDENTIAL 1 Endorphins and their receptors. Endomorphin-1 Tyr – Pro – Trp – Phe – NH2 Endomorphin-2 Tyr – Pro – Phe – Phe – NH2 2 2 Drug Discovery : designing the ideal opioid (From B.L. Kieffer, Nature (2016), 537, 170-171) 3 Three levels of pain control by endogenous opioid system (EOS) EOS EOS Attacking pain at EOS its source Relieving or reducing pain at its source More than 50% of MO effects are attributable to peripheral neurons (nociceptors) Roques, B.P., Fournié-Zaluski, M.C. and Wurm, M., Nature Reviews Drug Discovery, 2012 4 DENKIs: mechanism of action The endogenous opioid system (EOS) is present at all levels of physiological-nociceptive control i.e. periphery, spinal cord and brain Elements of the EOS are opioid receptors, enkephalins and their inactivating enzymes Dual Inhibitors of ENKephalinases (DENKIs) potentiate physiological functions of DENKI enkephalins (e.g. pain control) only on those pathways where they are tonically released Enkephalinases APN NEP No adverse effects Enkephalins Y G G F M(L) (endogenous) Opioid receptors Morphine indiscriminatingly overstimulates all opioid receptors including those not involved in (Morphine) pain control (exogenous) Adverse effects 5 Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets in a murine model of bone cancer-induced pain. 6 Distribution of MOR, DOR and NEP and APN in rat brain. Effect rhizotomy (right) on MOR, DOR and NEP. NEP Mu Delta APN [3H]HACBOGly* [3H]DAMGO* [3H]DTLET* [125I]RB 129** * Waksman et al., Proc. Natl. Acad. Sci. (1986) Waksman et al., EMBO J. (1986) ** Noble et al., Neuroscience (2001) Waksman et al., C. R. Acad. Sci. (1984). 7 Pharmacological effects of pre-proenkephalin (PENK) gene KO in mice i.c.v. ENKs : transient MO-like antinociceptive effect at high doses due to rapid metabolism i.c.v. in mice ED50 MO : 0.63 nmol/mouse; ED50 Met-E : 330 nmol/mouse (Interussi, PNAS 1980) ED50 Met-E+kelatorphan (50 µg) : 1,2 nmol/mouse (Fournié-Zaluski, EJP 1984) 100 250 * 80 Hot plate test 200 ) Wild type 60 150 KO preproenK 40 100 * Baseline jump latency (s) jump Baseline latency * * 20 (s latency Jump 50 * 0 0 +/+ -/- +/+ 0 20 0 20 RB101 (20 mg/kg i.v.) Naloxone * P < 0.05 ; ** P < 0.01 as compared to wild-type control mice *** P < 0.001 No change in morphine-induced Cutt-off 240 s antinociceptive effetc in PENK-KO mice. A physiological enkephalin tone DENKIs’ antinociceptive effects are is active in pain control specifically related to enkephalin protection König et al. Nature (1996) Noble F., Psychopharmacol. (2008) 8 Pharmacological effects of pre-proenkephalin (PENK) gene KO in mice i.c.v. ENKs : transient MO-like antinociceptive effect at high doses due to rapid metabolism i.c.v. in mice ED50 MO : 0.63 nmol/mouse; ED50 Met-E : 330 nmol/mouse (Interussi, PNAS 1980) ED50 Met-E+kelatorphan (50 µg) : 1,2 nmol/mouse (Fournié-Zaluski, EJP 1984) 100 250 * 80 Hot plate test 200 ) Wild type 60 150 KO preproenK 40 100 * Baseline jump latency (s) jump latency Baseline * * 20 (s latency Jump 50 * 0 0 +/+ -/- +/+ 0 20 0 20 RB101 (20 mg/kg i.v.) Naloxone * P < 0.05 ; ** P < 0.01 as compared to wild-type control mice *** P < 0.001 No change in morphine-induced Cutt-off 240 s antinociceptive effetc in PENK-KO mice. A physiological enkephalin tone DENKIs’ antinociceptive effects are is active in pain control specifically related to enkephalin protection König et al. Nature (1996) Noble F., Psychopharmacol. (2008) 9 Effect of DENKIs on the extracellular efflux of Met-enkephalin in the nucleus accumbens, periaqueductal grey (PAG) and cerebrospinal fluid (CSF) Microdialysis or superfusion in awake and freely moving rats Subarachnoidal Bourgoin S. et al., JPET, 1986. 10 Potentiation of the action of Met-enkephalin (ME) on locus coeruleus neurons by kelatorphan (20 µM). Lack of proper effect of kelatorphan Locus coeruleus : brain structure involved in central control of respiration and cardiac rhythm and at the source of physical symptoms of addiction Exogenous ME (or MO) applied by pressure pulse () on slice containing the LC, leads to hyperpolarization. The response is amplified by kelatorphan (J.T. Williams et al., J. Pharmacol. Exp. Ther., 243(1), 397-401, 1987) Kelatorphan alone is inactive suggesting a very low basal release of ENKs in this structure DENKIs have no detrimental effect on respiration and cardiac frequency (E. Boudinot et al., Pain 90, 7-13 (2001) 11 Puissance analgésique similaire de la morphine et des enképhalines par voie i.v. dans les modèles des douleurs aiguës. i.c.v. in mice ED50 MO : 0.63 nmol/mouse; ED50 Met-E : 330 nmol/mouse (Interussi, PNAS 1980) ED50 Met-E+kelatorphan (50 µg) : 1.2 nmol/mouse (Fournié-Zaluski, EJP 1984) Comparison between i.v. morphine and i.v. PL37 in the Hot Plate Test (HPT) vehicle (EtOH/cremophor/H2O) improving BBB crossing 100 *** PL37 ED par Toutes les 50 remplacement du réponses sont *** chrémophor ou du tween inhibées par pré- 80 par une cyclodextrine administration de *** utilisable chez l’homme naloxone 75 i.v. perf douleur aigüe ? MO, ED 1.6 mg/kg % analgesia % 50 PL37, ED 1.8 mg/kg 50 ** 50 *** % analgesia = 100 x (test latency – control ** p<0.01 ** vs. vehicle latency) / (cut-off time *** p<0.001 – control latency) Dunnett’s t test 25 1 mg/kg 2 mg/kg 3 mg/kg Morphine PL37 Analgesic effects of morphine or PL37 injected i.v. 10 min before the test in the hot plate test in mice (jump response). Points represent the percentage of analgesia for n = 8 mice Control group corresponds to i.v. administration of vehicle. 12 12 Very efficient potentiation of morphine antinociceptive effect induced by dual enkephalinase inhibitor RB101 in the hot-plate test and tail-flick test (not shown here) 5 10 20 0,5 0,5/5 0,5/10 0,5/20 mg/kg RB 101 Morphine Morphine/RB 101 same effect with PL37 13 Mechanism of action for peripheral analgesic effects of DENKIs- protected enkephalins in chronic pain and Ors hypersensitivity In models of neuropathic (CCI in rodents) and inflammatory pain, release and concentration of enkephalins increase constantly during a week or two before plateauing for as long as the injury lasts (Zollner et al. 2008) CFA 24 h–96 h CRF CRFR SP 12 h DOR MOR NEP 6 h APN DENKI Ca2+,K+ YGG untreated paw TRPV SV 1 DENKI AEA ORs strongly enhanced on APN noxious inputs each sides of nerve injury CFA, ipl injection day -6 to spinal cord (Truong et al. 2000) Roques, B.P., Fournié-Zaluski, M.C. and Wurm, M., NRDD, 2012 Roques, B.P., Fournié-Zaluski, M.C. and Wurm, M., NRDD Schafer, M. et al., Eur J Pharmacol (1995) (2012) NP, sciatic nerve ligation Pertovaara, A. and Wei, H., Eur J Pharmacol (2001) 14 PL37 reduction of neuropathic pain (allodynia and thermal hyperalgesia) induced by partial ligation of sciatic nerve in mice 10 mg/kg/po 20 mg/kg/po 40 mg/kg/po IPSILATERAL, sham-operated 1.3 IPSILATERAL, sciatic nerve injury 0.6 ***p<0.001 versus baseline values; ###p<0.001, #p<0.05 versus vehicle (post injection). 2-way ANOVA followed by Bonferroni’s multiple comparison test. Seltzer’s model 7 # # # vehicle 6 PL37, 10 mg/kg/po Plantar test 5 4 3 von Frey Test 2 paw withdrawalpaw(s) 1 0 Before admin. 20-40 mn of PL37 after gavage **p<0.001; *p<0.05 versus baseline values; ##p<0.01 ; #p<0.05 versus vehicle (post injection). 2 way ANOVA followed by Bonferroni’s multiple comparison test. The effect of PL37 is reversed by prior administration of naloxone methiodide (not shown here) 15 Antinociceptive effects of THC given in Effects induced by THC in combination with RB 101 combination with RB 101 in the hot plate test in on the suppression of conditioned suppression of mice motility test in mice, antagonism by SR-141,716A % of analgesia Counts Valverde et al., Eur. J. Neurosci. (2001) CONFIDENTIAL 16 Plurality of pain relief by dual enkephalinase inhibitors PL37 is active after oral administration on : 1°) model of inflammatory pain (carageenan) 2°) model of neuropathic pain, sciatic nerve ligation (Coll. R. Maldonado). 3°) Streptozotocin-induced model of diabetic neuropathy (coll. A. Eschalier). 4°) Osteosarcona-induced thermal hyperalgesia (Coll. A. Baamonde). Synergetic effects controlled by isobolographic analysis for all the models with different molecule acting on different opioid target. 17 Potentiation of the antihyperalgesic effect induced by ACEA (CB1 agonist) by the simultaneous per os of PL265 in mice intratibially inoculated with B16-F10 cells Synergistic effects involve interaction between cannabinoid and opioid receptors sytems 18 Potentiation of the antihyperalgesic effect induced by AM1241 (CB2 agonist) by the simultaneous per os of PL265 in mice Synergistic effects involve interaction with beta-endorphin released by the CB2 agonist, AM1241 19 Potentiation of the antihyperalgesic effect induced by URB-937 (FAAH inhibitor) by the simultaneous per os of PL265 in mice Synergistic effects involve interaction between PL265-protected-ENKs and URB937- protected-AEA degradation by FAAH 20 Effects of the administration of PL265 alone and combined drugs in mice intratibially inoculated with B16-F10 measured by the unilateral hot plate test.
Load more

Recommended publications
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Behavioral and Brain Sciences Plasticity: Implications for Opioid
    Behavioral and Brain Sciences http://journals.cambridge.org/BBS Additional services for Behavioral and Brain Sciences: Email alerts: Click here Subscriptions: Click here Commercial reprints: Click here Terms of use : Click here Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Behavioral and Brain Sciences / Volume 20 / Issue 03 / September 1997, pp 392 ­ 403 DOI: null, Published online: 08 September 2000 Link to this article: http://journals.cambridge.org/abstract_S0140525X97241488 How to cite this article: Anthony H. Dickenson (1997). Plasticity: Implications for opioid and other pharmacological interventions in specific pain states. Behavioral and Brain Sciences,20, pp 392­403 Request Permissions : Click here Downloaded from http://journals.cambridge.org/BBS, IP address: 144.82.107.43 on 10 Aug 2012 BEHAVIORAL AND BRAIN SCIENCES (1997) 20, 392±403 Printed in the United States of America Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Department of Pharmacology, University College London, London WC1E 6BT, United Kingdom Electronic mail: anthony.dickenson6ucl.ac.uk Abstract: The spinal mechanisms of action of opioids under normal conditions are reasonably well understood. The spinal effects of opioids can be enhanced or reduced depending on pathology and activity in other segmental and nonsegmental pathways. This plasticity will be considered in relation to the control of different pain states using opioids. The complex and contradictory findings on the supraspinal actions of opioids are explicable in terms of heterogeneous descending pathways to different spinal targets using multiple transmitters and receptors ± therefore opioids can both increase and decrease activity in descending pathways.
    [Show full text]
  • Cardioprotective Properties of Opioid Receptor Agonists in Rats with Stress-Induced
    Cardioprotective Properties of Opioid Receptor Agonists in Rats with Stress-Induced Cardiac Injury Ekaterina S. Prokudinaa B, Leonid N. Maslova* A, D, E, F, Natlia V. Naryzhnayaa B,G, Sergey Yu. Tsibulnikova B,C,E, Yury B. Lishmanova,b D, John E. Madias PhD c D,E, Peter R. Oeltgen PhD d D,E aLaboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences 634012 Tomsk, Russia. bLaboratory of Nuclear Medicine, National Research Tomsk Polytechnic University, Tomsk, Russia. cIcahn School of Medicine at Mount Sinai, and the Division of Cardiology, Elmhurst Hospital Center, New York, New York, USA. dDepartment of Pathology, University of Kentucky College of Medicine, Lexington, KY, USA * Correspondence: Leonid N. Maslov, MD, PhD, DSci, Professor of Pathological Physiology Laboratory of Experimental Cardiology, Federal State Budgetary Scientific Institution «Research Institute for Cardiology», Kyevskaya 111A, 634012 Tomsk, Russia Tel. +7 3822 262174 E-mail address: [email protected] Short title: Stress cardiomyopathy and opioid receptors Summary Purpose The objectives of this study were to investigate the role of endogenous opioids in the mediation of stress-induced cardiomyopathy (SIC), and to evaluate which opioid receptors regulate heart resistance to immobilization stress. Methods Wistar rats were subjected to 24 h 1 immobilization stress. Stress-induced heart injury was assessed by 99mTc-pyrophosphate accumulation in the heart. The opioid receptor (OR) antagonists (naltrexone, NxMB - naltrexone methyl bromide, MR 2266, ICI 174.864) and agonists (DALDA, DAMGO, DSLET, U-50,488) were administered intraperitoneally prior to immobilization and 12 h after the start of stress. In addition, the selective µ OR agonists PL017 and DAMGO were administered intracerebroventricularly prior to stress.
    [Show full text]
  • The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
    Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • (D-Ala*)Deltorphin II: D,-Dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens
    The Journal of Neuroscience, June 1991, 17(6): 1565-l 576 (D-Ala*)Deltorphin II: D,-dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens R. Longoni,’ L. Spina,’ A. Mulas,’ E. Carboni,’ L. Garau,’ P. Melchiorri,2 and G. Di Chiaral ‘Institute of Experimental Pharmacology and Toxicology, University of Cagliari, 09100 Cagliari, Italy and 21nstitute of Medical Pharmacology, University of Rome “La Sapienza,” 00185 Rome, Italy In order to investigate the relative role of central 6- and has been implicated in the stimulant actions of systemic opiates. F-opioid receptors in behavior, the effects of (D- Morphine-like opiates stimulate DA release preferentially in the Ala*)cleltorphin II, a natural Gopioid peptide, and PL017, nucleus accumbens (Di Chiara and Imperato, 1988a) and elicit a beta-casomorphin derivative specific for mu receptors, hypermotility sensitive to blockade by the DA D, receptor an- were compared after local intracerebral and intraventricular tagonist SCH 23390 (Longoni et al., 1987a). Intra-accumbens administration. lntracerebral infusion of the two peptides was infusion of opioid peptides elicits motor stimulation, but this done bilaterally in the limbic nucleus accumbens and in the action seems independent from DA, being resistant to classic ventral and dorsal caudate putamen of freely moving rats DA-receptor antagonists (neuroleptics; Pert and Sivit, 1977; Ka- through chronic intracerebral cannulas. After intra-accum- livas et al., 1983). Moreover, the syndrome elicited by intra- bens infusion, the two peptides elicited marked but opposite accumbens opiates is biphasic, as motor stimulation is typically behavioral effects: while (o-Ala2)deltorphin II evoked dose- preceded by motor inhibition and catalepsy (Costa11et al., 1978).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.247,609 B2 Roques Et Al
    USOO82476.09B2 (12) United States Patent (10) Patent No.: US 8.247,609 B2 Roques et al. (45) Date of Patent: Aug. 21, 2012 (54) AMINOACID DERIVATIVES CONTAININGA FOREIGN PATENT DOCUMENTS DSULFANYL GROUPIN THE FORM OF EP O262O53 3, 1988 MIXED DISULEANYLAND AMINOPEPTIDASEN INHIBITORS (Continued) (75) Inventors: Bernard Roques, Paris (FR): Marie-Claude Fournie-Zalluski, Paris OTHER PUBLICATIONS (FR) Silverman (The Organic Chemistry of Drug Design and Drug Action, (73) Assignee: Pharamleads, Paris (FR) 1992, Academic Press Inc.).* (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 U.S.C. 154(b) by 868 days. (21) Appl. No.: 12/146,941 Primary Examiner — Susanna Moore Assistant Examiner — Jennifer C Sawyer (22) Filed: Jun. 26, 2008 (74) Attorney, Agent, or Firm — Harness, Dickey & Pierce, (65) Prior Publication Data P.L.C. US 2009/OO12153 A1 Jan. 8, 2009 Related U.S. Application Data (57) ABSTRACT (63) Continuation-in-part of application No. 12/084,091, The invention relates to novel compounds of formula (I): filed as application No. PCT/EP2006/067711 on Oct. HN CH(R)-CH S S CH-CH(R) CONH 24, 2006. Rs, wherein R is a hydrocarbon chain, phenyl or benzyl (30) Foreign Application Priority Data radical, methylene radical substituted by a 5 or 6 atom het erocycle; R is a phenyl or benzyl radical, a 5 or 6 atom Oct. 25, 2005 (FR) ...................................... O5 10862 aromatic heterocycle, methylene group Substituted by a 5 or 6 May 5, 2006 (FR) ...................................... O6 O4030 atom heterocycle; Rs is a CH(R)—COOR radical, wherein R is hydrogen, an OH or OR group, a saturated hydrocarbon (51) Int.
    [Show full text]
  • Citation Classics and Trends in the Field of Opioids: a Bibliometric Analysis
    Open Access Original Article DOI: 10.7759/cureus.5055 Citation Classics and Trends in the Field of Opioids: A Bibliometric Analysis Hira F. Akbar 1 , Khadijah Siddiq 2 , Salman Nusrat 3 1. Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, PAK 2. Internal Medicine, Civil Hospital Karachi, Dow University of Health Sciences, Karachi, PAK 3. Gasteroenterology, University of Oklahoma Health Sciences Center, Oklahoma City, USA Corresponding author: Hira F. Akbar, [email protected] Abstract Introduction Bibliometric analysis is one of the emerging and latest statistical study type used to examine and keep a systemic record of the research done on a particular topic of a certain field. A number of such bibliometric studies are conducted on various topics of the medical science but none existed on the vast topic of pharmacology - opioids. Hence, we present a bibliometric analysis of the ‘Citation Classics’ of opioids. Method The primary database chosen to extract the citation classics of opioids was Scopus. Top 100 citation classics were arranged according to the citation count and then analyzed. Results The top 100 citation classics were published between 1957 and 2013, among which seventy-two were published from 1977 to 1997. Among all nineteen countries that contributed to these citation classics, United States of America alone produced sixty-three classics. The top three journals of the list were multidisciplinary and contained 36 citation classics. Endogenous opioids were the most studied (n=35) class of opioids among the citation classes and the most studied subject was of the neurosciences. Conclusion The subject areas of neurology and analgesic aspects of opioids are well established and endogenous and synthetic opioids were the most studied classes of opioids.
    [Show full text]
  • Rôles Des Récepteurs Nucléaires Nur77 Et Nor-1 Et Des
    Rôles des récepteurs nucléaires Nur77 et Nor-1 et des neuropeptides enképhaline et dynorphine dans les comportements médiés par la dopamine et induits par les psychostimulants Thèse Céline Hodler Programme de doctorat en Neurobiologie Philosophiae doctor (Ph.D.) Faculté de médecine Québec, Canada © Céline Hodler, 2012 RÉSUMÉ Cette thèse démontre que les récepteurs nucléaires Nur77 et Nor-1 ainsi que les neuropeptides dynorphine (DYN) et enképhaline (ENK) sont des facteurs déterminants de la régulation du système dopaminergique. Notre premier manuscrit démontre d’une part que Nur77 et Nor-1 sont très clairement impliqués dans la régulation de l’homéostasie du système dopaminergique et qu’ils y jouent des rôles distincts, voire opposés, dans les conditions basales et dans les réponses comportementales et biochimiques aux psychostimulants. La délétion génétique de Nur77 augmente la proportion des récepteurs D2 en haute affinité (D2high), supprime les stéréotypies et perturbe la persistance de la préférence de place induites par l’administration répétée de psychostimulants. À l’inverse, la délétion de Nor-1 diminue la proportion des récepteurs D2high, atténue les comportements moteurs en réponse à l’amphétamine et supprime la sensibilisation comportementale. La délétion de Nor-1 module également l’expression de la DYN et de l’ENK favorisant ainsi une diminution de la réponse comportementale alors que celle de Nur77 induit l’effet inverse. Ainsi, Nor-1 et Nur77 jouent des rôles opposés, la délétion de Nor-1 tempère les comportements moteurs, celle de Nur77 les exacerbe. Notre second manuscrit démontre d’autre part que la DYN et l’ENK sont toutes deux nécessaires et ont des rôles opposés dans la manifestation des comportements de base médiés par la dopamine.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Improving Naltrexone Compliance and Outcomes with Putative Pro
    Journal of Systems and Integrative Neuroscience Research Article ISSN: 2059-9781 Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual Kenneth Blum1*, Lisa Lott2, David Baron1, David E Smith3, Rajendra D Badgaiyan4 and Mark S Gold5 1Western University Health Sciences, Graduate College, Pomona, CA, USA 2Division of Behavioral Precision Management, Geneus Health, LLC, San Antonio, TX, USA 3Department of Pharmacology, University of California San Francisco School of Medicine, San Francisco, CA, USA 4Department of Psychiatry, Icahn School of Medicine Mt Sinai, New York, NY, USA and Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, San Antonio, TX, Long School of Medicine, University of Texas Medical Center, San Antonio, TX, USA 5Department of Psychiatry, Washington University School of Medicine, St. Louis, Mo, USA Abstract A recent analysis from Stanford University suggested that without any changes in currently available treatment, prevention, and public health approaches, we should expect to have 510,000 deaths from prescription opioids and street heroin from 2016 to 2025 in the US. In a recent review, Mayo Clinic Proceedings (October 2019), Gold and colleagues at Mayo Clinic reviewed the available medications used in opioid use disorders and concluded that in private and community practice adherence is more important as a limiting factor to retention, relapse, and repeat overdose. It is agreed that the primary utilization of known opioid agonists like methadone, buprenorphine and naloxone combinations, while useful as a way of reducing societal harm, is limited by 50% of more discontinuing treatment within 6 months, their diversion, and addiction liability.
    [Show full text]
  • Cayman Pain Research
    Pain Research The development of novel pain therapeutics relies on understanding the highly complex nociceptive signaling pathways. Cayman offers a select group of tools to study TRP ion channels, purinergic receptors, voltage-gated ion channels, and various G protein-coupled receptors (GPCRs) that are known to be expressed by nociceptive primary afferent nerves. Modulators of glutamate, GABA, and nicotinic acetylcholine receptors are also available. Pain Signal Pain Transmission Primary nociceptor afferents release neurotransmitters such as glutamate and prostaglandins, which bind to specific Glutamate, prostaglandins, etc. receptors on the postsynaptic membrane to transmit a pain signal. 2+ glutamate Ca prostaglandins cannabinoids opioids The antinociceptive response includes Mg2+ EP1 AMPA NMDA inhibitory interneurons, signaling via GABA CB OP receptors, that activate μ-opioid receptors, + Na Ca2+ among others. + 2+ 5-HT K Ca Action potentials Na+ GABA Inhibitory Inhibitory pathways descending from interneuron the brainstem release neurotransmitters Descending neuron from such as serotonin (5-HT) or activate small brainstem opioid-containing interneurons in the spinal dorsal horn to release opioid peptides. Pain Signal Image adapted from: Olesen, A.E., Andresen, T., Staahl, C., et al. Pharmacol. Rev. 64(3), 722-779 (2012). Ligand-Gated Ion Channels TRP Ion Channel Agonists and Antagonists Item No. Product Name Summary A competitive antagonist of capsaicin activation of TRPV1 (IC s = 24.5 and 85.6 nM for human 14715 AMG 9810 50 and rat,
    [Show full text]
  • Pharmacological Characterisation of the Highly Nav1.7 Selective Spider Venom Peptide Pn3a Received: 29 September 2016 Jennifer R
    www.nature.com/scientificreports OPEN Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a Received: 29 September 2016 Jennifer R. Deuis1, Zoltan Dekan1, Joshua S. Wingerd1, Jennifer J. Smith1, Accepted: 12 December 2016 Nehan R. Munasinghe2, Rebecca F. Bhola2, Wendy L. Imlach2, Volker Herzig1, Published: 20 January 2017 David A. Armstrong3, K. Johan Rosengren3, Frank Bosmans4, Stephen G. Waxman5, Sulayman D. Dib-Hajj5, Pierre Escoubas6, Michael S. Minett7, Macdonald J. Christie2, Glenn F. King1, Paul F. Alewood1, Richard J. Lewis1, John N. Wood7 & Irina Vetter1,8 Human genetic studies have implicated the voltage-gated sodium channel NaV1.7 as a therapeutic target for the treatment of pain. A novel peptide, μ-theraphotoxin-Pn3a, isolated from venom of the tarantula Pamphobeteus nigricolor, potently inhibits NaV1.7 (IC50 0.9 nM) with at least 40–1000- fold selectivity over all other NaV subtypes. Despite on-target activity in small-diameter dorsal root ganglia, spinal slices, and in a mouse model of pain induced by NaV1.7 activation, Pn3a alone displayed no analgesic activity in formalin-, carrageenan- or FCA-induced pain in rodents when administered systemically. A broad lack of analgesic activity was also found for the selective NaV1.7 inhibitors PF- 04856264 and phlotoxin 1. However, when administered with subtherapeutic doses of opioids or the enkephalinase inhibitor thiorphan, these subtype-selective NaV1.7 inhibitors produced profound analgesia. Our results suggest that in these inflammatory models, acute administration of peripherally restricted NaV1.7 inhibitors can only produce analgesia when administered in combination with an opioid. The pore-forming subunits of voltage-gated sodium channels (NaV) are integral membrane proteins that allow influx of sodium ions, which is essential for action potential generation and propagation in electrically excitable cells.
    [Show full text]